Effects of novel muscarinic M3 receptor ligand C1213 in pulmonary arterial hypertension models

Mohamed Ahmed, Sonya VanPatten, Satyanarayana Lakshminrusimha, Hardik Patel, Thomas R. Coleman, Yousef Al-Abed

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Pulmonary hypertension (PH) is a complex disease comprising a pathologic remodeling and thickening of the pulmonary vessels causing an after load on the right heart ventricle that can result in ventricular failure. Triggered by oxidative stress, episodes of hypoxia, and other undetermined causes, PH is associated with poor outcomes and a high rate of morbidity. In the neonate, this disease has a similar etiology but is further complicated by the transition to breathing after birth, which requires a reduction in vascular resistance. Persistent pulmonary hypertension of the newborn (PPHN) is one form of PH that is frequently unresponsive to current therapies including inhaled nitric oxide (due to lack of proper absorption and diffusion), and other therapeutics targeting signaling mediators in vascular endothelium and smooth muscle. The need for novel agents, which target distinct pathways in pulmonary hypertension, remains. Herein, we investigated the therapeutic effects of novel muscarinic receptor ligand C1213 in models of PH. We demonstrated that via M3 muscarinic receptors, C1213 induced activating- eNOS phosphorylation (serine-1177), which is known to lead to nitric oxide (NO) production in endothelial cells. Using signaling pathway inhibitors, we discovered that AKT and calcium signaling contributed to eNOS phosphorylation induced by C1213. As expected for an eNOS-stimulating agent, in ex vivo and in vivo models, C1213 triggered pulmonary vasodilation and induced both pulmonary artery and systemic blood pressure reductions demonstrating its potential value in PH and PPHN. In brief, this proof-of-concept study provides evidence that an M3 muscarinic receptor functionally selective ligand stimulates downstream pathways leading to antihypertensive effects using in vitro, ex vivo, and in vivo models of PH.

Original languageEnglish (US)
Article numbere13069
JournalPhysiological Reports
Volume4
Issue number24
DOIs
StatePublished - Dec 1 2016
Externally publishedYes

Fingerprint

Muscarinic M3 Receptors
Pulmonary Hypertension
Ligands
Persistent Fetal Circulation Syndrome
Heart Ventricles
Nitric Oxide
Phosphorylation
Lung
Calcium Signaling
Vascular Endothelium
Muscarinic Receptors
Therapeutic Uses
Vascular Smooth Muscle
Vasodilation
Vascular Resistance
Serine
Antihypertensive Agents
Pulmonary Artery
Respiration
Oxidative Stress

Keywords

  • C1213
  • Muscarinic receptor
  • Nitric oxide
  • PPHN
  • Pulmonary hypertension

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

Effects of novel muscarinic M3 receptor ligand C1213 in pulmonary arterial hypertension models. / Ahmed, Mohamed; VanPatten, Sonya; Lakshminrusimha, Satyanarayana; Patel, Hardik; Coleman, Thomas R.; Al-Abed, Yousef.

In: Physiological Reports, Vol. 4, No. 24, e13069, 01.12.2016.

Research output: Contribution to journalArticle

Ahmed, Mohamed ; VanPatten, Sonya ; Lakshminrusimha, Satyanarayana ; Patel, Hardik ; Coleman, Thomas R. ; Al-Abed, Yousef. / Effects of novel muscarinic M3 receptor ligand C1213 in pulmonary arterial hypertension models. In: Physiological Reports. 2016 ; Vol. 4, No. 24.
@article{45d75bf1cf9d40e298168ad7e3683966,
title = "Effects of novel muscarinic M3 receptor ligand C1213 in pulmonary arterial hypertension models",
abstract = "Pulmonary hypertension (PH) is a complex disease comprising a pathologic remodeling and thickening of the pulmonary vessels causing an after load on the right heart ventricle that can result in ventricular failure. Triggered by oxidative stress, episodes of hypoxia, and other undetermined causes, PH is associated with poor outcomes and a high rate of morbidity. In the neonate, this disease has a similar etiology but is further complicated by the transition to breathing after birth, which requires a reduction in vascular resistance. Persistent pulmonary hypertension of the newborn (PPHN) is one form of PH that is frequently unresponsive to current therapies including inhaled nitric oxide (due to lack of proper absorption and diffusion), and other therapeutics targeting signaling mediators in vascular endothelium and smooth muscle. The need for novel agents, which target distinct pathways in pulmonary hypertension, remains. Herein, we investigated the therapeutic effects of novel muscarinic receptor ligand C1213 in models of PH. We demonstrated that via M3 muscarinic receptors, C1213 induced activating- eNOS phosphorylation (serine-1177), which is known to lead to nitric oxide (NO) production in endothelial cells. Using signaling pathway inhibitors, we discovered that AKT and calcium signaling contributed to eNOS phosphorylation induced by C1213. As expected for an eNOS-stimulating agent, in ex vivo and in vivo models, C1213 triggered pulmonary vasodilation and induced both pulmonary artery and systemic blood pressure reductions demonstrating its potential value in PH and PPHN. In brief, this proof-of-concept study provides evidence that an M3 muscarinic receptor functionally selective ligand stimulates downstream pathways leading to antihypertensive effects using in vitro, ex vivo, and in vivo models of PH.",
keywords = "C1213, Muscarinic receptor, Nitric oxide, PPHN, Pulmonary hypertension",
author = "Mohamed Ahmed and Sonya VanPatten and Satyanarayana Lakshminrusimha and Hardik Patel and Coleman, {Thomas R.} and Yousef Al-Abed",
year = "2016",
month = "12",
day = "1",
doi = "10.14814/phy2.13069",
language = "English (US)",
volume = "4",
journal = "Physiological Reports",
issn = "2051-817X",
publisher = "John Wiley and Sons Inc.",
number = "24",

}

TY - JOUR

T1 - Effects of novel muscarinic M3 receptor ligand C1213 in pulmonary arterial hypertension models

AU - Ahmed, Mohamed

AU - VanPatten, Sonya

AU - Lakshminrusimha, Satyanarayana

AU - Patel, Hardik

AU - Coleman, Thomas R.

AU - Al-Abed, Yousef

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Pulmonary hypertension (PH) is a complex disease comprising a pathologic remodeling and thickening of the pulmonary vessels causing an after load on the right heart ventricle that can result in ventricular failure. Triggered by oxidative stress, episodes of hypoxia, and other undetermined causes, PH is associated with poor outcomes and a high rate of morbidity. In the neonate, this disease has a similar etiology but is further complicated by the transition to breathing after birth, which requires a reduction in vascular resistance. Persistent pulmonary hypertension of the newborn (PPHN) is one form of PH that is frequently unresponsive to current therapies including inhaled nitric oxide (due to lack of proper absorption and diffusion), and other therapeutics targeting signaling mediators in vascular endothelium and smooth muscle. The need for novel agents, which target distinct pathways in pulmonary hypertension, remains. Herein, we investigated the therapeutic effects of novel muscarinic receptor ligand C1213 in models of PH. We demonstrated that via M3 muscarinic receptors, C1213 induced activating- eNOS phosphorylation (serine-1177), which is known to lead to nitric oxide (NO) production in endothelial cells. Using signaling pathway inhibitors, we discovered that AKT and calcium signaling contributed to eNOS phosphorylation induced by C1213. As expected for an eNOS-stimulating agent, in ex vivo and in vivo models, C1213 triggered pulmonary vasodilation and induced both pulmonary artery and systemic blood pressure reductions demonstrating its potential value in PH and PPHN. In brief, this proof-of-concept study provides evidence that an M3 muscarinic receptor functionally selective ligand stimulates downstream pathways leading to antihypertensive effects using in vitro, ex vivo, and in vivo models of PH.

AB - Pulmonary hypertension (PH) is a complex disease comprising a pathologic remodeling and thickening of the pulmonary vessels causing an after load on the right heart ventricle that can result in ventricular failure. Triggered by oxidative stress, episodes of hypoxia, and other undetermined causes, PH is associated with poor outcomes and a high rate of morbidity. In the neonate, this disease has a similar etiology but is further complicated by the transition to breathing after birth, which requires a reduction in vascular resistance. Persistent pulmonary hypertension of the newborn (PPHN) is one form of PH that is frequently unresponsive to current therapies including inhaled nitric oxide (due to lack of proper absorption and diffusion), and other therapeutics targeting signaling mediators in vascular endothelium and smooth muscle. The need for novel agents, which target distinct pathways in pulmonary hypertension, remains. Herein, we investigated the therapeutic effects of novel muscarinic receptor ligand C1213 in models of PH. We demonstrated that via M3 muscarinic receptors, C1213 induced activating- eNOS phosphorylation (serine-1177), which is known to lead to nitric oxide (NO) production in endothelial cells. Using signaling pathway inhibitors, we discovered that AKT and calcium signaling contributed to eNOS phosphorylation induced by C1213. As expected for an eNOS-stimulating agent, in ex vivo and in vivo models, C1213 triggered pulmonary vasodilation and induced both pulmonary artery and systemic blood pressure reductions demonstrating its potential value in PH and PPHN. In brief, this proof-of-concept study provides evidence that an M3 muscarinic receptor functionally selective ligand stimulates downstream pathways leading to antihypertensive effects using in vitro, ex vivo, and in vivo models of PH.

KW - C1213

KW - Muscarinic receptor

KW - Nitric oxide

KW - PPHN

KW - Pulmonary hypertension

UR - http://www.scopus.com/inward/record.url?scp=85008386303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008386303&partnerID=8YFLogxK

U2 - 10.14814/phy2.13069

DO - 10.14814/phy2.13069

M3 - Article

C2 - 28039410

AN - SCOPUS:85008386303

VL - 4

JO - Physiological Reports

JF - Physiological Reports

SN - 2051-817X

IS - 24

M1 - e13069

ER -